Navigation Links
Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greece's Leading Biotech Magazine

SANTA MONICA, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company ( focused on bringing the life saving potential of stem cells to families nationwide and internationally, today announced that CEO Matthew L. Schissler was interviewed by the leading biotechnology publication in Greece, where Cord Blood America established a partnership in 2006 named a.bourkas Co., United.

"Stem cells are used today in the treatment of leukemia, breast cancer, lymphoma, Hodgkin's Disease, aplastic anemia, sickle cell anemia, various other cancers, blood diseases, hereditary and genetic conditions and immune system disorders," Mr. Schissler said in the interview. "As stem cell transplants become routine, they may be used to fight many other cancers, viruses and genetic disorders."

"Umbilical cord stem cells are used to repopulate one's immune system. An example would be a leukemia patient who undergoes radiation therapy. The stem cells from the umbilical cord repopulate the patient's immune system with healthy cells to keep the body strong and to help fight other diseases," Cord Blood America's CEO said.

Mr. Schissler further explained that, "umbilical cord stem cells are a perfect match for the baby, but because of close genetic ties, there is a good chance they will match for immediate family members as well. They also may be a very good match for a sibling. Umbilical cord stem cells are the best because they have hematapoletic traits, meaning they repopulate the immune system and have regenerative traits meaning they can regenerate tissue."

Andreas Bourkas, Director and Manager of a.bourkas Co., United, said saving the umbilical cord at birth is starting to be a popular choice. "Greek's have very strong family ties and this is exactly the right step for a family to take," Mr. Bourkas said. Mr. Schissler said this is Cord Blood America's first international business and the success of the business model could lead to introducing the concept in other countries."

About Cord Blood America

Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at For investor information, visit


Paul Knopick

E & E Communications


SOURCE Cord Blood America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CORD:USE Cord Blood Bank Announces the Addition of Dr. John Wagner, a Pioneer in the Use of Umbilical Cord Blood Stem Cells, to Its Scientific Advisory Board
2. National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. Video and Photo: Tekturna HCT(R), a Single-tablet Combination of Tekturna(R)* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
5. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
6. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
7. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
8. 49th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases
9. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
10. Cord Blood America Announces Financing
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. ... the faculty of the University of North Carolina Kenan-Flagler Business School ... entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading ...
(Date:6/27/2016)...   Ginkgo Bioworks , a leading organism ... today awarded as one of the World Economic ... most innovative companies. Ginkgo Bioworks is engineering biology ... world in the nutrition, health and consumer goods ... customers including Fortune 500 companies to design microbes ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016 On Monday, the Department of ... to share solutions for the Biometric Exit Program. The ... Border Protection (CBP), explains that CBP intends to add ... the United States , in order to ... imposters. Logo - ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):